Immunological therapies targeting leukemia

• DOI: 10.30574/gscbps.2024.29.2.0434
• Publication Date: 2024-11-26T10:09:51Z
• Authors: Cynthia Nayeli Q...; Daniela Córdova ...; Eymmy Elizabeth ...; Fernanda Zairemg...; Brissia Lazalde; Jesús Ernesto La...
• Keywords: Tumor microenvironment; CAR-T cells; Monoclonal antibodies; Toxicity in immunotherapy; Biomarkers; Hematopoietic stem cells

Leukemia represents one of the greatest challenges in medical oncology due to its aggressiveness and biological complexity. Immunotherapy has recently emerged as a promising option for treatment leukemias, however, genetic complexity represented challenge it. ALL AML present different alterations, such mutations, chromosomal rearrangements signaling pathways. Currently, several therapies have been investigated applied try treat leukemia, among them, CAR T-cell therapy shown great effectiveness, monoclonal antibodies are another option, immune checkpoint inhibitors also developed, use CAR-NK cells offers alternative, usual, stem cell transplantation remains an important curative option. treatments continue be renewed updated make them less toxic aggressive patients.